Treatment with Cosequin® of Bilateral Coxofemoral Osteoarthritis in a Great Dane

Compendium on Continuing Education for the Practicing Veterinarian

Volumn 23, Issue 10, 2001, Pages 888-894

  Hoffman, Allison R ^a  

^a OKLAHOMA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA;

EID: 0346404004     PISSN: 01931903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Johnson KA, Hulse DA, Hart RC, et al: Effects of an orally administered mixture of chondroitin sulfate, glucosamine hydrochloride and manganese ascorbate on synovial fluid chondroitin sulfate 3B3 and 7D4 epitope in a canine cruciate ligament transection model of osteoarthritis. Osteoarthritis Cartilage 9(1):14-21, 2001.
2. MacPhail CM, Lappin MR, Meyer DJ, et al: Hepatocellular toxicosis associated with administration of carprofen in 21 dogs. JAVMA 212(12): 1895-1901, 1998.
3. CVM update on Rimadyl®. Available at: http://www.fda.gov/cvm/index/updates/rimadyl2.html; updated December 7, 1999.
4. Forrester SD, Troy GC: Renal effects of nonsteroidal antiinflammatory drugs. Compend Contin Educ Pract Vet 21(10):910-919, 1999.
5. Dingle JT: The effect of NSAIDs on human articular cartilage glycosaminoglycan synthesis. Eur J Rheumatol Inflamm 16(1):47-52, 1996.
6. Brandt KD: Effects of nonsteroidal anti-inflammatory drugs on chondrocyte metabolism in vitro and in vivo. Am J Med 83(Suppl 5A):29-34, 1997.
7. Palmoski MJ, Brandt KD: Effects of some nonsteroidal antiinflammatory drugs on proteoglycan metabolism and organization in canine articular cartilage. Arthritis Rheum 23(9):1010-1020, 1980.
8. Benton HP, Vasseur PB, Broderick-Villa GA, Koolpe M: Effect of carprofen on sulfated glycosaminoglycan metabolism, protein synthesis, and prostaglandin release by cultured osteoarthritic canine chondrocytes. Am J Vet Res 58(3):286-292, 1997.
9. Hulse DS: Treatment methods for pain in the osteoarthritic patient. Vet Clin North Am Small Anim Pract 28(2):361-375, 1998.
10. McNamara PS, Johnston SA, Todhunter RJ: Slow-acting, disease-modifying, osteoarthritis agents. Vet Clin North Am Small Anim Pract 27(4): 863-881, 1997.
11. Huber ML, Bill RL: The use of polysulfated glycosaminoglycan in dogs. Compend Contin Educ Pract Vet 16(4): 501-506, 1994.
12. Lust G, Williams A, Burton-Wurster N, et al: Effects of intramuscular administration of glycosaminoglycan polysulfates on signs of incipient hip dysplasia in growing pups. Am J Vet Res 53(10):1836-1843, 1992.
13. Canapp SO, McLaughlin RM, Hoskinson JJ, et al: Scintigraphic evaluation of glucosamine HCl and chondroitin sulfate as treatment for acute synovitis in dogs. Am J Vet Res 60(12): 1550-1556, 1999.
14. Lippiello L, Woodward J, Karpman R, Hammad T: In vivo chondroprotection and metabolic synergy of glucosamine and chondroitin sulfate. Clin Orthopedics Related Res 381:229-240, 2000.
15. Lippiello L, Idouraine A, McNamara PS, et al: Cartilage stimulatory and antiproteolytic activity is present in sera of dogs treated with a chondroprotective agent. Canine Pract 24(1):18-21, 1999.
16. Hulse DS, Hart D, Slatter M, Beale BS: The effects of Cosequin® in cranial cruciate deficient and reconstructed stifle joints in dogs. Vet Orthop Soc 25th Annu Conf:64, 1998.
17. McNamara PS, Barr SC, Erb HN: Hematologic, hemostatic, and biochemical effects in dogs receiving an oral chondroprotective agent for thirty days. Am J Vet Res 57(9):1390-1394, 1996.
18. McNamara PS, Barr SC, Erb HN, Barlow LL: Hematological, hemostatic and biochemical effects in cats receiving an oral chondroprotective agent for thirty days. Vet Ther 1(2):108-117, 2000.
19. Hanson RR, Smalley LR, Huff GK, et al: Oral treatment with a glucosamine-chondroitin sulfate compound for degenerative joint disease in horses: 25 cases. Equine Pract 19(9): 16-22, 1997.
20. Hanson RR, Brawner WR, Blaik MA, et al: Oral treatment with a nutraceutical (Cosequin®) for ameliorating signs of navicular syndrome in horses. Vet Ther 2(2):148-159, 2001.
21. Liang Z, Leslie J, Adebowale A, et al: Determination of the nutraceutical, glucosamine hydrochloride, in raw materials, dosage forms and plasma using pre-column derivatization with ultravoilet HPLC. J Pharm Biomed Anal 20:807-814, 1999.
22. Deal CL, Moskowitz RW: Nutraceuticals as therapeutic agents in osteoarthritis: The role of glucosamine, chondroitin sulfate, and collagen hydrolysate. Rheum Dis Clin North Am 25(2):379-395, 1999.
23. Conte A, Volpi N, Palmieri L: Biochemical and pharmacokinetic aspects of oral treatment with chondroitin sulphate. Arzniemittelforschung 45(8): 918-925, 1995.
24. Adebowale A, Cox D, Eddington N: Analysis of glucosamine and chondroitin sulfate content in marketed products and the Caco-2 permeability of chondroitin sulfate raw materials. JANA 3(1):37-44, 2000.
25. McAlindon TE, LaValley MP, Culin JP, Felson DT: Glucosamine and chondroitin for treatment of osteoarthritis: A systematic quality assessment and meta-analysis. JAMA 283 (11):1469-1475, 2000.
26. Uebelhart D, Thonar EJMA, Delmus PD: Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: A pilot study. Osteoarthritis Cartilage 6(Suppl A):39-46, 1998.
27. Morreale P, Manopulo R, Galati M: Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. J Rheumatol 23:1385-1391, 1996.
28. Blanco FJ, Maneiro E, deToro FJ, et al: Effect of different extracellular matrix components on nitric oxide production by human osteoarthritic chondrocytes. Int Symp Regulatory Issues 7(Suppl A):S16, 1999.
29. Grand DA, O'Grady C, Garone E, et al: Chondroprotective and gene expression effects of nutritional supplements on articular cartilage. Osteoarthritis Cartilage 8(Suppl B):S34-S35, 2000.
30. Anderson MA, Slater MR, Hammad TA: Results of a survey of small animal practitioners on the perceived clinical efficacy and safety of an oral nutraceutical. Prev Vet Med 38:65-73, 1999.
31. Das Jr A, Hammad TA: Efficacy of a combination of FCHG49 glucosamine hydrochloride, TRH122 low molecular weight sodium chondroitin sulfate and manganese ascorbate in the management of knee osteoarthritis. Osteoarthritis Cartilage 8(5):343-350, 2000.
32. Leffler CT, Philippi AF, Leffler SG, et al: Glucosamine, chondroitin, and manganese ascorbate for degenerative joint disease of the knee or low back: A randomized, double-blind, placebo-controlled pilot study. Mil Med 164(2):85-91, 1999.
33. Beren J, Hill SL, Diener-West M, Rose NR: The effect of pre-loading oral glucosamine/chondroitin sulfate/manganese ascorbate combination on experimental arthritis in rats. Exp Biol Med 226(2):144-152, 2001.
34. Anderson MA: Oral chondroprotective agents. Part I. Common compounds. Compend Contin Educ Pract Vet 21(7):601-609, 1999.
35. Anderson MA: Oral chondroprotective agents. Part II. Evaluation of products. Compend Contin Educ Pract Vet 21(9):861-865, 1999.
36. Horstman J: The Arthritis Foundation's Guide to Alternative Therapies. Atlanta, GA, The Arthritis Foundation, 1999, pp 179-180.
37. Verbruggen G, Goemaere S, Veys EM: Chondroitin sulfate: S/DMOAD (structure/disease modifying anti-arthritis drug) in the treatment of finger joint osteoarthritis. Osteoarthritis Cartilage 6(Suppl A):37-38, 1998.
38. Barr ARS, Denny HR, Gibbs C: Clinical hip dysplasia in growing dogs: The long-term results of conservative management. J Small Anim Pract 28:243, 1987.